Drug intelligence / Profile preview

KDB2401

Development stage: Preclinical
Lead developer: Kyungdong Pharmaceutical

Overview

KDB2401 is a biologic therapeutic candidate being developed by Kyungdong Pharmaceutical for the treatment of atopic dermatitis. As of late 2025, the program is in the preclinical stage of development. While the specific molecular target has not been publicly disclosed, the drug is part of Kyungdong's pipeline of innovative biologics aimed at addressing chronic inflammatory skin conditions. The development of KDB2401 represents the company's strategic expansion into the biologics sector to provide new treatment options for patients with dermatological diseases.

Beyond the preview

Go deeper on KDB2401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KDB2401.

Explore the full profile